These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

615 related articles for article (PubMed ID: 29168357)

  • 1. Predictors of methotrexate response in Turkish children with oligoarticular and polyarticular juvenile idiopathic arthritis.
    Batu ED; Sönmez HE; Gülhan B; Arıcı ZS; Topaloğlu R; Bilginer Y
    Turk J Pediatr; 2017; 59(1):6-12. PubMed ID: 29168357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. When should the use of biological agents be considered in persistent oligoarticular juvenile idiopathic arthritis patients?
    Polat MC; Çelikel E; Tekin ZE; Kurt T; Kaplan MM; Güngörer V; Tekgöz N; Sezer M; Karagöl C; Coşkun S; Öner N; Sezer S; Acar BÇ
    Eur J Pediatr; 2024 Jun; 183(6):2725-2731. PubMed ID: 38554171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The extended oligoarticular subtype is the best predictor of methotrexate efficacy in juvenile idiopathic arthritis.
    Ravelli A; Viola S; Migliavacca D; Ruperto N; Pistorio A; Martini A
    J Pediatr; 1999 Sep; 135(3):316-20. PubMed ID: 10484796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Juvenile Arthritis Disease Activity Score proves to be a useful tool in treat-to-target therapy in juvenile idiopathic arthritis.
    Swart JF; van Dijkhuizen EHP; Wulffraat NM; de Roock S
    Ann Rheum Dis; 2018 Mar; 77(3):336-342. PubMed ID: 29138257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of methotrexate intolerance in juvenile idiopathic arthritis: a prospective, observational cohort study.
    van Dijkhuizen EH; Bulatović Ćalasan M; Pluijm SM; de Rotte MC; Vastert SJ; Kamphuis S; de Jonge R; Wulffraat NM
    Pediatr Rheumatol Online J; 2015; 13():5. PubMed ID: 25745368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of methotrexate efficacy and adverse events in patients with juvenile idiopathic arthritis: a systematic literature review.
    van Dijkhuizen EH; Wulffraat NM
    Pediatr Rheumatol Online J; 2014; 12():51. PubMed ID: 25525416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytokine Biomarkers of Disease Activity and Therapeutic Response after Initiating Methotrexate Therapy in Patients with Juvenile Idiopathic Arthritis.
    Funk RS; Chan MA; Becker ML
    Pharmacotherapy; 2017 Jun; 37(6):700-711. PubMed ID: 28475276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose methotrexate treatment for oligoarticular juvenile idiopathic arthritis nonresponsive to intra-articular corticosteroids.
    Brik R; Gepstein V; Berkovitz D
    Clin Rheumatol; 2005 Nov; 24(6):612-4. PubMed ID: 15877178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ; LIVER LESION IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS WITH DIFFERENT DURATION OF METHOTREXATE TREATMENT.
    Panko N; Tsiura O; Shevchenko N; Zimnytska T
    Georgian Med News; 2020; (304-305):95-99. PubMed ID: 32965257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A longterm prospective real-life experience with leflunomide in juvenile idiopathic arthritis.
    Alcântara AC; Leite CA; Leite AC; Sidrim JJ; Silva FS; Rocha FA
    J Rheumatol; 2014 Feb; 41(2):338-44. PubMed ID: 24334641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tocilizumab treatment in juvenile idiopathic arthritis patients: A single center experience.
    Demir S; Sönmez HE; Arslanoğlu-Aydın E; Özen S; Bilginer Y
    Turk J Pediatr; 2019; 61(2):180-185. PubMed ID: 31951328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of methotrexate in children with rheumatic diseases.
    Gutiérrez-Suárez R; Burgos-Vargas R
    Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S122-7. PubMed ID: 21044445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of children with oligoarticular juvenile idiopathic arthritis compared to polyarthritis on methotrexate- data of the German BIKER registry.
    Raab A; Kallinich T; Huscher D; Foeldvari I; Weller-Heinemann F; Dressler F; Kuemmerle-Deschner JB; Klein A; Horneff G
    Pediatr Rheumatol Online J; 2021 Mar; 19(1):41. PubMed ID: 33752685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of long-term remission of oligo/polyarticular juvenile idiopathic arthritis with S100A12 and vascular endothelial growth factor.
    Yamasaki Y; Takei S; Imanaka H; Nerome Y; Kubota T; Nonaka Y; Akaike H; Takezaki T; Kawano Y
    Mod Rheumatol; 2016 Jul; 26(4):551-6. PubMed ID: 26474088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methotrexate treatment may prevent uveitis onset in patients with juvenile idiopathic arthritis: experiences and subgroup analysis in a cohort with frequent methotrexate use.
    Kostik MM; Gaidar EV; Hynnes AY; Dubko MF; Masalova VV; Snegireva LS; Chikova IA; Isupova EA; Nikitina TN; Serogodskaya ED; Kalashnikova OV; Ravelli A; Chasnyk VG
    Clin Exp Rheumatol; 2016; 34(4):714-8. PubMed ID: 27385618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methotrexate treatment in juvenile idiopathic arthritis: when is the right time to stop?
    Foell D; Frosch M; Schulze zur Wiesch A; Vogl T; Sorg C; Roth J
    Ann Rheum Dis; 2004 Feb; 63(2):206-8. PubMed ID: 14722212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinically inactive disease in a cohort of children with new-onset polyarticular juvenile idiopathic arthritis treated with early aggressive therapy: time to achievement, total duration, and predictors.
    Wallace CA; Giannini EH; Spalding SJ; Hashkes PJ; O'Neil KM; Zeft AS; Szer IS; Ringold S; Brunner HI; Schanberg LE; Sundel RP; Milojevic DS; Punaro MG; Chira P; Gottlieb BS; Higgins GC; Ilowite NT; Kimura Y; Johnson A; Huang B; Lovell DJ;
    J Rheumatol; 2014 Jun; 41(6):1163-70. PubMed ID: 24786928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prediction rule for lack of achievement of inactive disease with methotrexate as the sole disease-modifying antirheumatic therapy in juvenile idiopathic arthritis.
    Bava C; Mongelli F; Pistorio A; Bertamino M; Bracciolini G; Dalprà S; Davì S; Lanni S; Muratore V; Pederzoli S; Rosina S; Schiappapietra B; Suffia C; Varnier G; Verazza S; Giancane G; Consolaro A; Ravelli A
    Pediatr Rheumatol Online J; 2019 Jul; 17(1):50. PubMed ID: 31345226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors determining resistance to conventional disease-modifying anti-rheumatic drug treatment in oligoarticular juvenile idiopathic arthritis.
    Sener S; Aliyev E; Batu ED; Balik Z; Bayindir Y; Cam V; Basaran O; Bilginer Y; Ozen S
    Clin Rheumatol; 2024 Jun; 43(6):2021-2026. PubMed ID: 38683443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of poor response to methotrexate in polyarticular-course juvenile idiopathic arthritis: analysis of the PRINTO methotrexate trial.
    Vilca I; Munitis PG; Pistorio A; Ravelli A; Buoncompagni A; Bica B; Campos L; Häfner R; Hofer M; Ozen S; Huemer C; Bae SC; Sztajnbok F; Arguedas O; Foeldvari I; Huppertz HI; Gamir ML; Magnusson B; Dressler F; Uziel Y; van Rossum MA; Hollingworth P; Cawkwell G; Martini A; Ruperto N;
    Ann Rheum Dis; 2010 Aug; 69(8):1479-83. PubMed ID: 20525842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.